Ajanta Pharma Future Growth
Future criteria checks 3/6
Ajanta Pharma is forecast to grow earnings and revenue by 16.7% and 12.2% per annum respectively. EPS is expected to grow by 16.3% per annum. Return on equity is forecast to be 23.3% in 3 years.
Key information
16.7%
Earnings growth rate
16.3%
EPS growth rate
Pharmaceuticals earnings growth | 17.6% |
Revenue growth rate | 12.2% |
Future return on equity | 23.3% |
Analyst coverage | Good |
Last updated | 31 Jan 2025 |
Recent future growth updates
Ajanta Pharma Limited Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Feb 02Revenue Beat: Ajanta Pharma Limited Exceeded Revenue Forecasts By 5.3% And Analysts Are Updating Their Estimates
Oct 31Ajanta Pharma Limited Just Recorded A 11% EPS Beat: Here's What Analysts Are Forecasting Next
Aug 04Recent updates
Ajanta Pharma Limited Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Feb 02With EPS Growth And More, Ajanta Pharma (NSE:AJANTPHARM) Makes An Interesting Case
Dec 15Revenue Beat: Ajanta Pharma Limited Exceeded Revenue Forecasts By 5.3% And Analysts Are Updating Their Estimates
Oct 31Here's Why Ajanta Pharma (NSE:AJANTPHARM) Has Caught The Eye Of Investors
Sep 10We Think Ajanta Pharma (NSE:AJANTPHARM) Can Manage Its Debt With Ease
Aug 23Ajanta Pharma Limited Just Recorded A 11% EPS Beat: Here's What Analysts Are Forecasting Next
Aug 04Some Confidence Is Lacking In Ajanta Pharma Limited's (NSE:AJANTPHARM) P/E
Aug 01With EPS Growth And More, Ajanta Pharma (NSE:AJANTPHARM) Makes An Interesting Case
Jun 01Ajanta Pharma Limited (NSE:AJANTPHARM) Analysts Are Pretty Bullish On The Stock After Recent Results
May 05Ajanta Pharma Limited's (NSE:AJANTPHARM) Intrinsic Value Is Potentially 23% Below Its Share Price
Apr 05We Think Ajanta Pharma (NSE:AJANTPHARM) Can Manage Its Debt With Ease
Feb 23Ajanta Pharma Limited (NSE:AJANTPHARM) Investors Are Less Pessimistic Than Expected
Dec 23Ajanta Pharma (NSE:AJANTPHARM) Seems To Use Debt Quite Sensibly
Aug 26These 4 Measures Indicate That Ajanta Pharma (NSE:AJANTPHARM) Is Using Debt Reasonably Well
Feb 07Here's Why Ajanta Pharma (NSE:AJANTPHARM) Has Caught The Eye Of Investors
Oct 24Estimating The Intrinsic Value Of Ajanta Pharma Limited (NSE:AJANTPHARM)
Aug 25Is Now The Time To Put Ajanta Pharma (NSE:AJANTPHARM) On Your Watchlist?
Jul 19A Look At The Intrinsic Value Of Ajanta Pharma Limited (NSE:AJANTPHARM)
Apr 28Ajanta Pharma (NSE:AJANTPHARM) Seems To Use Debt Quite Sensibly
Mar 14I Built A List Of Growing Companies And Ajanta Pharma (NSE:AJANTPHARM) Made The Cut
Feb 06Estimating The Fair Value Of Ajanta Pharma Limited (NSE:AJANTPHARM)
Dec 13Ajanta Pharma (NSE:AJANTPHARM) Will Pay A Dividend Of ₹9.50
Oct 31Here's Why We Think Ajanta Pharma (NSE:AJANTPHARM) Is Well Worth Watching
Sep 22Is Ajanta Pharma Limited (NSE:AJANTPHARM) Trading At A 27% Discount?
Sep 08Does Ajanta Pharma (NSE:AJANTPHARM) Have A Healthy Balance Sheet?
Aug 26Here's Why Shareholders Will Not Be Complaining About Ajanta Pharma Limited's (NSE:AJANTPHARM) CEO Pay Packet
Jul 07Should You Be Adding Ajanta Pharma (NSE:AJANTPHARM) To Your Watchlist Today?
Jun 14Is Ajanta Pharma Limited (NSE:AJANTPHARM) Trading At A 30% Discount?
May 15Ajanta Pharma Limited (NSE:AJANTPHARM) Vies For A Place In Your Dividend Portfolio: Here's Why
Apr 10Ajanta Pharma Limited's (NSE:AJANTPHARM) Has Had A Decent Run On The Stock market: Are Fundamentals In The Driver's Seat?
Mar 11Does Ajanta Pharma (NSE:AJANTPHARM) Deserve A Spot On Your Watchlist?
Feb 24Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
3/31/2027 | 59,166 | 12,921 | 9,967 | N/A | 7 |
3/31/2026 | 52,179 | 10,869 | 8,372 | N/A | 9 |
3/31/2025 | 46,104 | 9,255 | 8,072 | N/A | 8 |
12/31/2024 | 45,318 | 8,979 | N/A | N/A | N/A |
9/30/2024 | 44,908 | 8,750 | 9,127 | 11,625 | N/A |
6/30/2024 | 43,326 | 8,538 | N/A | N/A | N/A |
3/31/2024 | 42,087 | 8,162 | 6,327 | 7,851 | N/A |
12/31/2023 | 40,365 | 7,357 | N/A | N/A | N/A |
9/30/2023 | 39,031 | 6,602 | 6,610 | 8,199 | N/A |
6/30/2023 | 38,128 | 6,215 | N/A | N/A | N/A |
3/31/2023 | 37,426 | 5,880 | 6,176 | 7,921 | N/A |
12/31/2022 | 37,311 | 6,169 | N/A | N/A | N/A |
9/30/2022 | 35,972 | 6,742 | 5,027 | 6,613 | N/A |
6/30/2022 | 35,439 | 7,136 | N/A | N/A | N/A |
3/31/2022 | 33,410 | 7,127 | 4,129 | 5,617 | N/A |
12/31/2021 | 32,275 | 7,207 | N/A | N/A | N/A |
9/30/2021 | 31,384 | 7,056 | 3,607 | 5,379 | N/A |
6/30/2021 | 29,695 | 6,799 | N/A | N/A | N/A |
3/31/2021 | 28,897 | 6,539 | 4,047 | 5,763 | N/A |
12/31/2020 | 28,148 | 6,238 | N/A | N/A | N/A |
9/30/2020 | 27,173 | 5,547 | 3,593 | 5,334 | N/A |
6/30/2020 | 26,441 | 5,008 | N/A | N/A | N/A |
3/31/2020 | 25,879 | 4,677 | 2,174 | 4,568 | N/A |
12/31/2019 | 24,211 | 4,274 | N/A | N/A | N/A |
9/30/2019 | 22,550 | 3,868 | 1,451 | 4,409 | N/A |
6/30/2019 | 21,563 | 3,958 | N/A | N/A | N/A |
3/31/2019 | 20,554 | 3,870 | 315 | 3,745 | N/A |
12/31/2018 | 20,654 | 3,926 | N/A | N/A | N/A |
9/30/2018 | 21,674 | 4,731 | N/A | N/A | N/A |
6/30/2018 | 21,636 | 4,796 | N/A | N/A | N/A |
3/31/2018 | 21,258 | 4,686 | N/A | 2,811 | N/A |
12/31/2017 | 20,590 | 4,882 | N/A | N/A | N/A |
9/30/2017 | 20,050 | 4,833 | N/A | N/A | N/A |
6/30/2017 | 19,805 | 4,821 | N/A | N/A | N/A |
3/31/2017 | 19,833 | 5,068 | N/A | 6,093 | N/A |
12/31/2016 | 19,386 | 4,908 | N/A | N/A | N/A |
9/30/2016 | 18,821 | 4,622 | N/A | N/A | N/A |
6/30/2016 | 18,072 | 4,350 | N/A | N/A | N/A |
3/31/2016 | 17,340 | 4,156 | N/A | 3,261 | N/A |
12/31/2015 | 16,809 | 3,692 | N/A | N/A | N/A |
9/30/2015 | 16,160 | 3,510 | N/A | N/A | N/A |
6/30/2015 | 15,502 | 3,340 | N/A | N/A | N/A |
3/31/2015 | 14,736 | 3,099 | N/A | 2,794 | N/A |
3/31/2014 | 12,083 | 2,339 | N/A | 2,124 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AJANTPHARM's forecast earnings growth (16.7% per year) is above the savings rate (6.7%).
Earnings vs Market: AJANTPHARM's earnings (16.7% per year) are forecast to grow slower than the Indian market (18.2% per year).
High Growth Earnings: AJANTPHARM's earnings are forecast to grow, but not significantly.
Revenue vs Market: AJANTPHARM's revenue (12.2% per year) is forecast to grow faster than the Indian market (11% per year).
High Growth Revenue: AJANTPHARM's revenue (12.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: AJANTPHARM's Return on Equity is forecast to be high in 3 years time (23.3%)
Discover growth companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/02/01 20:49 |
End of Day Share Price | 2025/01/31 00:00 |
Earnings | 2024/12/31 |
Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Ajanta Pharma Limited is covered by 26 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Rashmi Sancheti Shetty | Anand Rathi Shares and Stock Brokers Limited |
null null | Anand Rathi Shares and Stock Brokers Limited |
null null | Asian Markets Securities Private Limited |